Annual FCF
-$3.85 M
-$1.86 M-93.10%
31 December 2023
Summary:
Protagenic Therapeutics annual free cash flow is currently -$3.85 million, with the most recent change of -$1.86 million (-93.10%) on 31 December 2023. During the last 3 years, it has fallen by -$2.50 million (-185.71%). PTIX annual FCF is now -265.67% below its all-time high of $2.33 million, reached on 31 December 2008.PTIX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly FCF
-$185.70 K
+$1.37 M+88.03%
30 September 2024
Summary:
Protagenic Therapeutics quarterly free cash flow is currently -$185.70 thousand, with the most recent change of +$1.37 million (+88.03%) on 30 September 2024. Over the past year, it has increased by +$525.90 thousand (+73.90%). PTIX quarterly FCF is now -103.03% below its all-time high of $6.13 million, reached on 30 September 2008.PTIX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM FCF
-$4.64 M
+$525.90 K+10.19%
30 September 2024
Summary:
Protagenic Therapeutics TTM free cash flow is currently -$4.64 million, with the most recent change of +$525.90 thousand (+10.19%) on 30 September 2024. Over the past year, it has dropped by -$1.84 million (-65.78%). PTIX TTM FCF is now -217.94% below its all-time high of $3.93 million, reached on 30 June 2009.PTIX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PTIX Free Cash Flow Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -93.1% | +73.9% | -65.8% |
| 3 y3 years | -185.7% | +82.7% | -70.8% |
| 5 y5 years | -259.8% | -200.5% | -617.1% |
PTIX Free Cash Flow High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -185.7% | at low | -2.6% | +88.8% | -139.6% | +10.2% |
| 5 y | 5 years | -689.7% | at low | -200.5% | +88.8% | -849.8% | +10.2% |
| alltime | all time | -265.7% | +65.9% | -103.0% | +96.6% | -217.9% | +66.1% |
Protagenic Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$185.70 K(-88.0%) | -$4.64 M(-10.2%) |
| June 2024 | - | -$1.55 M(-6.5%) | -$5.16 M(+0.4%) |
| Mar 2024 | - | -$1.66 M(+34.0%) | -$5.14 M(+33.4%) |
| Dec 2023 | -$3.85 M(+93.1%) | -$1.24 M(+74.0%) | -$3.85 M(+37.8%) |
| Sept 2023 | - | -$711.60 K(-53.5%) | -$2.80 M(+6.7%) |
| June 2023 | - | -$1.53 M(+312.0%) | -$2.62 M(+35.4%) |
| Mar 2023 | - | -$371.80 K(+105.5%) | -$1.94 M(-2.9%) |
| Dec 2022 | -$2.00 M(-28.7%) | -$180.90 K(-66.2%) | -$1.99 M(-10.1%) |
| Sept 2022 | - | -$535.20 K(-36.8%) | -$2.22 M(-19.6%) |
| June 2022 | - | -$847.10 K(+96.7%) | -$2.76 M(+5.2%) |
| Mar 2022 | - | -$430.60 K(+6.3%) | -$2.62 M(-6.3%) |
| Dec 2021 | -$2.80 M(+107.5%) | -$405.10 K(-62.3%) | -$2.80 M(+3.1%) |
| Sept 2021 | - | -$1.08 M(+51.4%) | -$2.71 M(+25.9%) |
| June 2021 | - | -$710.40 K(+16.9%) | -$2.16 M(+35.5%) |
| Mar 2021 | - | -$607.70 K(+89.4%) | -$1.59 M(+18.0%) |
| Dec 2020 | -$1.35 M(+176.4%) | -$320.90 K(-38.0%) | -$1.35 M(+14.6%) |
| Sept 2020 | - | -$517.80 K(+255.4%) | -$1.18 M(+63.2%) |
| June 2020 | - | -$145.70 K(-60.0%) | -$721.30 K(+9.9%) |
| Mar 2020 | - | -$364.40 K(+143.9%) | -$656.40 K(+34.5%) |
| Dec 2019 | -$488.00 K(-54.4%) | -$149.40 K(+141.7%) | -$488.00 K(-24.5%) |
| Sept 2019 | - | -$61.80 K(-23.5%) | -$646.40 K(-13.1%) |
| June 2019 | - | -$80.80 K(-58.8%) | -$744.20 K(-26.2%) |
| Mar 2019 | - | -$196.00 K(-36.3%) | -$1.01 M(-5.9%) |
| Dec 2018 | -$1.07 M(-22.4%) | -$307.80 K(+92.9%) | -$1.07 M(-9.3%) |
| Sept 2018 | - | -$159.60 K(-53.7%) | -$1.18 M(-14.4%) |
| June 2018 | - | -$344.80 K(+33.1%) | -$1.38 M(+7.6%) |
| Mar 2018 | - | -$259.00 K(-37.9%) | -$1.28 M(-7.1%) |
| Dec 2017 | -$1.38 M(+21.0%) | -$417.00 K(+16.2%) | -$1.38 M(+5.8%) |
| Sept 2017 | - | -$358.80 K(+45.3%) | -$1.30 M(+5.0%) |
| June 2017 | - | -$246.90 K(-30.9%) | -$1.24 M(-13.8%) |
| Mar 2017 | - | -$357.40 K(+4.6%) | -$1.44 M(+26.3%) |
| Dec 2016 | -$1.14 M(+200.9%) | -$341.80 K(+15.4%) | -$1.14 M(+26.1%) |
| Sept 2016 | - | -$296.10 K(-33.5%) | -$904.60 K(+27.3%) |
| June 2016 | - | -$445.10 K(+675.4%) | -$710.50 K(+97.1%) |
| Mar 2016 | - | -$57.40 K(-45.8%) | -$360.40 K(-9.0%) |
| Dec 2015 | - | -$106.00 K(+3.9%) | -$396.00 K(-1.2%) |
| Sept 2015 | - | -$102.00 K(+7.4%) | -$401.00 K(+5.8%) |
| June 2015 | -$379.00 K(-52.1%) | -$95.00 K(+2.2%) | -$379.00 K(+2.2%) |
| Mar 2015 | - | -$93.00 K(-16.2%) | -$371.00 K(-5.8%) |
| Dec 2014 | - | -$111.00 K(+38.8%) | -$394.00 K(-9.2%) |
| Sept 2014 | - | -$80.00 K(-8.0%) | -$434.00 K(-45.1%) |
| June 2014 | -$791.00 K(+144.1%) | -$87.00 K(-25.0%) | -$791.00 K(+12.4%) |
| Mar 2014 | - | -$116.00 K(-23.2%) | -$704.00 K(+19.7%) |
| Dec 2013 | - | -$151.00 K(-65.4%) | -$588.00 K(+34.6%) |
| Sept 2013 | - | -$437.00 K(+48.6%) | -$437.00 K(-93.7%) |
| June 2013 | -$324.00 K(-97.1%) | - | - |
| Sept 2011 | - | -$294.00 K(-91.8%) | -$6.94 M(-30.7%) |
| June 2011 | - | -$3.60 M(-24.6%) | -$10.03 M(-13.8%) |
| Mar 2011 | - | -$4.77 M(-377.9%) | -$11.63 M(+3.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2010 | -$11.29 M(+205.4%) | $1.72 M(-150.8%) | -$11.29 M(-17.5%) |
| Sept 2010 | - | -$3.38 M(-35.0%) | -$13.68 M(+10.4%) |
| June 2010 | - | -$5.20 M(+17.1%) | -$12.39 M(+62.1%) |
| Mar 2010 | - | -$4.44 M(+557.2%) | -$7.64 M(+106.7%) |
| Dec 2009 | -$3.70 M(-258.9%) | -$675.00 K(-67.6%) | -$3.70 M(-13.8%) |
| Sept 2009 | - | -$2.09 M(+367.7%) | -$4.29 M(-209.2%) |
| June 2009 | - | -$446.00 K(-9.0%) | $3.93 M(-482.7%) |
| Mar 2009 | - | -$490.00 K(-61.4%) | -$1.03 M(-144.2%) |
| Dec 2008 | $2.33 M(-142.5%) | -$1.27 M(-120.7%) | $2.33 M(+65.2%) |
| Sept 2008 | - | $6.13 M(-213.5%) | $1.41 M(-128.4%) |
| June 2008 | - | -$5.40 M(-288.7%) | -$4.96 M(+126.5%) |
| Mar 2008 | - | $2.86 M(-231.0%) | -$2.19 M(-60.0%) |
| Dec 2007 | -$5.48 M(-741.2%) | -$2.19 M(+830.2%) | -$5.48 M(+66.4%) |
| Sept 2007 | - | -$235.00 K(-91.1%) | -$3.29 M(+7.0%) |
| June 2007 | - | -$2.63 M(+522.2%) | -$3.07 M(+275.5%) |
| Mar 2007 | - | -$423.00 K(+2036.4%) | -$818.80 K(+840.1%) |
| Dec 2006 | $854.00 K(-823.7%) | - | - |
| Oct 2006 | - | -$19.80 K(-94.7%) | -$87.10 K(-26.2%) |
| July 2006 | - | -$376.00 K(-208.0%) | -$118.00 K(-145.7%) |
| July 2006 | -$118.00 K(+168.2%) | - | - |
| Apr 2006 | - | $348.10 K(-983.5%) | $258.00 K(-386.3%) |
| Jan 2006 | - | -$39.40 K(-22.3%) | -$90.10 K(+77.7%) |
| Oct 2005 | - | -$50.70 K(-95.1%) | -$50.70 K(-105.1%) |
| July 2005 | -$44.00 K(-94.8%) | - | - |
| July 2004 | -$842.00 K(-249.6%) | - | - |
| Apr 2003 | - | -$1.03 M(-196.8%) | $985.00 K(-58.3%) |
| Jan 2003 | - | $1.06 M(-220.9%) | $2.36 M(+230.6%) |
| Oct 2002 | - | -$879.00 K(-148.0%) | $715.00 K(+27.0%) |
| July 2002 | $563.00 K(-226.2%) | $1.83 M(+422.9%) | $563.00 K(-55.6%) |
| Apr 2002 | - | $350.00 K(-159.7%) | $1.27 M(-544.9%) |
| Jan 2002 | - | -$586.00 K(-43.2%) | -$285.00 K(-63.1%) |
| Oct 2001 | - | -$1.03 M(-140.7%) | -$772.00 K(+73.1%) |
| July 2001 | -$446.00 K(-260.4%) | $2.54 M(-310.7%) | -$446.00 K(-90.2%) |
| Apr 2001 | - | -$1.20 M(+12.1%) | -$4.53 M(+183.3%) |
| Jan 2001 | - | -$1.07 M(+52.2%) | -$1.60 M(+203.6%) |
| Oct 2000 | - | -$705.00 K(-54.6%) | -$527.00 K(-289.6%) |
| July 2000 | $278.00 K(-108.6%) | -$1.55 M(-189.7%) | $278.00 K(+148.2%) |
| Apr 2000 | - | $1.73 M(>+9900.0%) | $112.00 K(-104.4%) |
| Jan 2000 | - | $0.00(-100.0%) | -$2.52 M(-10.6%) |
| Oct 1999 | - | $100.00 K(-105.8%) | -$2.82 M(-12.4%) |
| July 1999 | -$3.22 M(+544.9%) | -$1.72 M(+90.9%) | -$3.22 M(-223.7%) |
| Apr 1999 | - | -$900.00 K(+200.0%) | $2.60 M(0.0%) |
| Jan 1999 | - | -$300.00 K(0.0%) | $2.60 M(-534.2%) |
| Oct 1998 | - | -$300.00 K(-107.3%) | -$599.00 K(+20.0%) |
| July 1998 | -$499.00 K(-78.3%) | $4.10 M(-555.7%) | -$499.00 K(-89.2%) |
| Apr 1998 | - | -$900.00 K(-74.3%) | -$4.60 M(+24.3%) |
| Jan 1998 | - | -$3.50 M(+1650.0%) | -$3.70 M(+1750.0%) |
| Oct 1997 | - | -$200.00 K | -$200.00 K |
| July 1997 | -$2.30 M | - | - |
FAQ
- What is Protagenic Therapeutics annual free cash flow?
- What is the all time high annual FCF for Protagenic Therapeutics?
- What is Protagenic Therapeutics annual FCF year-on-year change?
- What is Protagenic Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Protagenic Therapeutics?
- What is Protagenic Therapeutics quarterly FCF year-on-year change?
- What is Protagenic Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Protagenic Therapeutics?
- What is Protagenic Therapeutics TTM FCF year-on-year change?
What is Protagenic Therapeutics annual free cash flow?
The current annual FCF of PTIX is -$3.85 M
What is the all time high annual FCF for Protagenic Therapeutics?
Protagenic Therapeutics all-time high annual free cash flow is $2.33 M
What is Protagenic Therapeutics annual FCF year-on-year change?
Over the past year, PTIX annual free cash flow has changed by -$1.86 M (-93.10%)
What is Protagenic Therapeutics quarterly free cash flow?
The current quarterly FCF of PTIX is -$185.70 K
What is the all time high quarterly FCF for Protagenic Therapeutics?
Protagenic Therapeutics all-time high quarterly free cash flow is $6.13 M
What is Protagenic Therapeutics quarterly FCF year-on-year change?
Over the past year, PTIX quarterly free cash flow has changed by +$525.90 K (+73.90%)
What is Protagenic Therapeutics TTM free cash flow?
The current TTM FCF of PTIX is -$4.64 M
What is the all time high TTM FCF for Protagenic Therapeutics?
Protagenic Therapeutics all-time high TTM free cash flow is $3.93 M
What is Protagenic Therapeutics TTM FCF year-on-year change?
Over the past year, PTIX TTM free cash flow has changed by -$1.84 M (-65.78%)